Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Dianthus Therapeutics Inc.(DNTH)
Top performer 
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for DNTH
11/11/2026: DNTH (4-star) is currently NOT-A-BUY. Pass it for now.
Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for severe autoimmune and inflammatory diseases. Its primary asset, DNTH-103, seeks to inhibit the complement system, a complex biological area with significant market potential. The company’s strengths include a streamlined operational focus following its 2023 merger, though it remains pre-revenue and dependent on successful clinical trial results. Major risks include intense competition from established pharmaceutical players and the inherent uncertainty of drug development. The stock is best suited for risk-tolerant, long-term investors monitoring clinical trial readouts, as the company requires further capital and regulatory progress to reach its long-term potential.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward potential based on its clinical pipeline but lacks the revenue growth seen in mature companies. |
| Momentum investor | Mixed fit | Momentum fits only if positive clinical data triggers an upward price trend, as the stock is highly news-driven. |
| Value investor | Weak fit | The company does not generate earnings or cash flow, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | Dianthus is a pre-revenue company that does not pay dividends. |
| Low-risk investor | Weak fit | The high volatility and binary risks of clinical-stage biotech make this unsuitable for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to large price swings based on clinical trial results and financing needs. |
| Valuation risk | High | Valuation is highly speculative, as it relies on the future success of unproven drug candidates. |
| Competition risk (complement inhibitors) | High | Dianthus competes against major pharmaceutical companies with established market presence. |
| Business quality | Medium | While the platform is scientifically focused, the business lacks the stability of commercial operations. |
| Dividend income | Low / none | There is no income generation for shareholders. |
| Execution risk | High | Failure to execute clinical trials according to timeline or regulatory standards could jeopardize the company's future. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 248.24% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/11/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Sector & Industry Intelligence
Sector snapshot as of 2026-11-10
Sector
Healthcare
- Signal
- Constructive
- Sentiment
- Strong Bullish
- Market state
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 60.0%
- Active BUY / eligible
- 69 / 115
- 22-session BUY-count change
- +29
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Biotechnology
- BUY participation
- 43.5%
- Active BUY / eligible
- 20 / 46
- 22-session BUY-count change
- +12
The sector signal does not change this stock’s BUY, SELL, or PASS advisory.
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.00B USD | Price to earnings Ratio - | 1Y Target Price 139.25 |
Price to earnings Ratio - | 1Y Target Price 139.25 | ||
Volume (30-day avg) 923.9K shares | Beta 0.26 | 52 Weeks Range 34.29 - 117.88 | Updated Date 11/10/2026 |
52 Weeks Range 34.29 - 117.88 | Updated Date 11/10/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.08 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Research and clinical development of DNTH-103 and pipeline candidates. | The company currently spends money rather than making it, with the long-term goal of obtaining regulatory approval to sell drug products. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4.23B | Price to Sales(TTM) 1840 |
Enterprise Value 4.23B | Price to Sales(TTM) 1840 | ||
Enterprise Value to Revenue 1556.87 | Enterprise Value to EBITDA -7.35 | Shares Outstanding 56.31M | Shares Floating 56.23M |
Shares Outstanding 56.31M | Shares Floating 56.23M | ||
Percent Insiders 0.12 | Percent Institutions 130.01 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.